PPIB and Alzheimer disease: While most developed AD drugs aim to inhibit β- and γ-secretases, prevent Aβ aggregation, or utilize anti-Aβ antibodies to promote Aβ aggregate clearance from the brain (Cummings et al., 2022; Karran and de Strooper, 2022), we propose a new enzymatic approach of using a novel soluble form of ADAM10 for the treatment of AD.